510(k) Report

De Novo · Granted

Granted

Curetis Unyvero LRT Application

DEN170047De NovoGranted Apr 3, 2018204-day reviewClass II21 CFR 866.3985

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Curetis GmbH · QBH Lower Respiratory Microbial Nucleic Acid Detection System

Granted on Apr 3, 2018 as a new device type through De Novo after a 204-day review. 4 later devices descend from it.

Decided
Apr 3, 2018
Review
204 days
Class
Class II
Product code
QBH
Recalls
None

4 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2018: 1 descendant cleared2019: 1 descendant cleared2021: 1 descendant cleared2024: 1 descendant cleared201620182020202220242026
  1. This deviceDEN170047 Curetis Unyvero LRT ApplicationCuretis GmbH · 2018
  2. Descendant · cites it directly · 2 of its ownK180966 FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2018 · Recalled
  3. Descendant · 2 generations on · 1 of its ownK212727 FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2021 · Recalled
  4. Descendant · 3 generations on · 0 of its ownK243222 BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel)…Biofire Diagnostics, LLC (Biomerieux) · 2024 · Recalled
  5. Descendant · cites it directly · 0 of its ownK191967 Unyvero LRT BAL ApplicationCuretis GmbH · 2019

Most influential descendants

Showing 4 of 4 · See all
  • K180966FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2018 · cites it directly2descendants
  • K212727FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2021 · 2 generations on1descendant
  • K243222BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE® FILMARRAY®…Biofire Diagnostics, LLC (Biomerieux) · 2024 · 3 generations on0descendants
  • K191967Unyvero LRT BAL ApplicationCuretis GmbH · 2019 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN170047Curetis Unyvero LRT ApplicationCuretis GmbH2018—
+1K180966FilmArray Pneumonia PanelBiofire Diagnostics, LLC20184
+2K212727FilmArray Pneumonia PanelBiofire Diagnostics, LLC20211
+3K243222BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE®…Biofire Diagnostics, LLC (Biomerieux)20243
+1K191967Unyvero LRT BAL ApplicationCuretis GmbH2019—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201810
201910
202110
202410
FIG. 1 — Lineage of DEN170047, 2018–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QBH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (4)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K180966FilmArray Pneumonia PanelBiofire Diagnostics, LLC20182
K191967Unyvero LRT BAL ApplicationCuretis GmbH20190

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K180966 (Biofire Diagnostics, LLC, 2018) has gone furthest, with 2 descendants of its own.

How does its category compare?

All QBH devices

QBH Lower Respiratory Microbial Nucleic Acid Detection System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · QBH

1in 2019

2018: 12019: 1
2007high 1 (2018) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QBH

Too few QBH 510(k)s in any year since 2007 to give a median.

Recalls per year · QBH

1in 2023

2023: 1
2007high 1 (2023) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · QBH

No MAUDE report names QBH since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20181—00
20191—00
20200—00
20210—00
20220—00
20230—10
20240—00
20250—00
20260—0—

What is it indicated for?

The Unyvero LRT Application is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of nucleic acid sequences from the following microorganisms and antibiotic resistance markers in endotracheal aspirates from adult hospitalized patients with suspected lower respiratory tract infections. Microorganism — Associated antibiotic resistance marker Acinetobacter spp.ᵃ — ctx-Mᵇ, kpc, ndm, oxa-23, oxa-24, oxa-58…

Read the full statement (453 words)

The Unyvero LRT Application is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of nucleic acid sequences from the following microorganisms and antibiotic resistance markers in endotracheal aspirates from adult hospitalized patients with suspected lower respiratory tract infections.

Microorganism — Associated antibiotic resistance marker

Acinetobacter spp.ᵃ — ctx-Mᵇ, kpc, ndm, oxa-23, oxa-24, oxa-58, vim

Chlamydia pneumoniae —

Citrobacter freundii — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Enterobacter cloacae complexᶜ — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Escherichia coli — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Haemophilus influenzae — tem

Klebsiella oxytoca — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Klebsiella pneumoniaeᵈ — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Klebsiella variicola — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Legionella pneumophila —

Moraxella catarrhalis —

Morganella morganii — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Mycoplasma pneumoniae —

Proteus spp.ᵉ — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Pseudomonas aeruginosa — ctx-Mᵇ, kpc, ndm, vim

Serratia marcescens — ctx-Mᵇ, kpc, ndm, oxa-48, vim

Staphylococcus aureus — mecA

Stenotrophomonas maltophilia —

Streptococcus pneumoniae —

ᵃ Acinetobacter spp. includes: A. baumannii, A. calcoaceticus, A. haemolyticus, A. junii, A. lwoffii, A. nosocomialis, A. parvus, A. pittii, (detected by LRT Application) and A. ursingii (not detected by LRT Application).

ᵇ ctx-M1 subgroup.

ᶜ Enterobacter cloacae complex includes: E. asburiae, E. cloacae, E. hormaechei, E. kobei, E. ludwigii, and E. xiangfangensis.

ᵈ Klebsiella pneumoniae includes two variants: K. pneumoniae (variant 1), and K. quasipneumoniae (variant 2)

ᵉ Proteus spp. includes P. hauseri, P. mirabilis, P. penneri and P. vulgaris.

The Unyvero LRT Application performed on the Unyvero System is indicated as an aid in the diagnosis of lower respiratory tract infection in adult hospitalized patients with signs and symptoms of lower respiratory infection; results should be used in conjunction with other clinical and laboratory findings. As tracheal aspirates commonly contain colonizing microorganisms, detection of Unyvero LRT microbial targets does not indicate that the microorganism is the cause of the disease. Unyvero positive results do not rule out co-infection with microorganisms not detected by the Unyvero LRT Application. Negative results do not preclude lower respiratory infection, as the causative agent may be a microorganism not detected by this test.

A negative result for any antibiotic resistance marker does not indicate that detected microorganisms are susceptible to applicable antimicrobial agents. Detected resistance markers cannot be definitively linked to specific microorganisms, and may be present in organisms that are not detected by the Unyvero LRT Application such as organisms present as colonizing or normal flora.

Microbiology cultures of aspirates should be performed to obtain isolates for species identification and antimicrobial susceptibility testing, to differentiate quantities of identified microorganisms as well as normal flora present in the specimen and to identify potential microorganisms not targeted by the Unyvero LRT Application.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN170047: Curetis Unyvero LRT Application.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN170047

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026